（来源：团结报） 转自：团结报 □ 李经纬 本书首次纳入外用经典名方，按剂型分类，共有汤剂、醋剂、酒（酊）剂等11类剂型。每首方的方源， 介绍古代医学典籍一个或数个，同一个方的出处，除刊载古代医籍外，对现代皮科专家亦记载文献作 者，从中领略当代使用古代外用名方情况。 名医验方 汇聚名家 本书收录1911年后皮科、外科名医为主的内、外用验方各100首，验方作者为近代名医、皮科大家丁德 恩、张锡纯、丁甘仁等，国医大师禤国维、陈彤云、干祖望等，全国名老中医艾儒棣、肖定远，岐黄学 者白彦萍、刘红霞、陈达灿等，共达百名，均为国内外知名专家。 内用验方按功效分为19节，每首验方包括代号名、验方、功效药理、主治、辨证化裁、用法、注意事 项、方源8项。外用验方与古代外用经典名方分类基本相同，增加乳膏剂。 辨证论治 多有创新 本书第一章中医皮肤医药发展简史，概括介绍皮肤医药学发展的悠久历史、皮肤解剖生理的发展史，总 结出皮科学的定义和发展史。 本书扼要介绍中医基础理论，将复杂深奥的理论简明化，以简驭繁。介绍医门八法，即汗、和、下、 消、吐、清、温、补八法，成为治疗总则。同时，专列中药配方颗粒，介绍发展历程与展望及其调配。 由马 ...

Group 1 - Heng Rui Medicine's subsidiary received approval for the innovative drug Rilaforpu α injection (brand name: Aizeli®), marking it as the world's first PD-L1/TGF-βRII bispecific antibody fusion protein approved for advanced gastric cancer treatment [1] - The approval highlights the innovative mechanism of Aizeli, which overcomes the immune suppression microenvironment, filling a clinical treatment gap and showcasing the global competitiveness of domestic innovative drugs [1] Group 2 - Anlong Bio announced the completion of nearly 100 million yuan in B+ round financing, with investments from Beijing's pharmaceutical health industry investment fund and the Shunyi Airport Industrial Fund [2] - The company also established an international strategic cooperation agreement in the small nucleic acid drug field with a NASDAQ-listed company, with a cooperation scale exceeding 100 million USD, indicating significant progress in international business development [2] Group 3 - Yifan Pharmaceutical's wholly-owned subsidiary received a drug registration acceptance notice for Yihuang Decoction granules, which is the company's first classic prescription variety aimed at treating kidney deficiency and dampness [3] - The acceptance of this classic prescription is expected to accelerate approval and broaden the company's traditional Chinese medicine innovation pipeline due to the scarcity of similar competing products [3] Group 4 - Weili Medical projected a net profit decrease of 57% to 66% for the fiscal year 2025, estimating a profit of 75 million to 95 million yuan, a decline of 144 million to 124 million yuan compared to the previous year [4] - The profit drop is attributed to subsidiary performance issues and goodwill impairment, indicating short-term profit pressure, with the recovery of core business and overseas capacity release being critical for future performance [4] Group 5 - Borui Bio submitted its IPO application for listing in Hong Kong, with the prospectus now publicly available [5] - The company has eight commercialized products, including two innovative drugs and six mature products, with significant revenue derived from Adalimumab and Zibotuzumab [5] - As of September 30, 2025, Borui Bio reported nearly 1.2 billion yuan in cash reserves, and the company completed a financing round of 540 million yuan in 2022, achieving a post-investment valuation of 13.5 billion yuan [5]